Related Experiment Video
Updated: Sep 21, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
[Rapid and ultrarapid insulins: when and how?]
Yann Vuignier1, Anne Wojtusciszyn1, Christophe Kosinski1
1Service d'endocrinologie, diabétologie et métabolisme, Centre hospitalier universitaire vaudois, 1011 Lausanne.
Revue Medicale Suisse
|June 1, 2022
Summary
Ultra-rapid insulins offer faster absorption for improved mealtime flexibility in diabetes management. These advanced insulin formulations enhance convenience without altering overall diabetes control.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Insulin therapy is crucial for managing type 1 diabetes and may be necessary for other diabetes types with insulin deficiency.
- Standard short-acting insulins aim to replicate mealtime insulin release but have a notable absorption delay.
- This delay can limit the effectiveness and practical use of short-acting insulins.
Purpose of the Study:
- To introduce ultra-rapid insulin analogues designed for faster absorption.
- To evaluate their potential to better mimic physiological insulin response to meals.
- To assess their impact on treatment flexibility and insulin pump therapy.
Main Methods:
- Development of novel ultra-rapid insulin analogues.
- Pharmacokinetic studies assessing absorption profiles.
- Clinical evaluation of flexibility and usability in diabetes management.
Main Results:
- Ultra-rapid insulins demonstrate significantly faster absorption compared to conventional short-acting insulins.
- These analogues provide more flexibility for mealtime insulin administration.
- No significant improvement in overall diabetes control was observed.
Conclusions:
- Ultra-rapid insulins offer enhanced pharmacokinetic profiles for improved convenience.
- They represent a valuable option for increasing flexibility in mealtime insulin dosing.
- These analogues are also suitable for use in continuous subcutaneous insulin infusion therapy via insulin pumps.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
279
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
279
01:16Insulin: Dosing Regimen and Adverse Effects
277
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
277
01:06Oral Hypoglycemic Agents: Glinides
276
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
276
01:25Insulin: Biosynthesis, Chemistry, and Preparation
571
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
571
01:25Routes of Drug Administration: Parenteral
2.2K
The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
2.2K
01:29Drug Delivery: Parenteral Route
914
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
914